UCB

UCB is a global biopharmaceutical company headquartered in Brussels, Belgium, that researches, develops and delivers medicines for people living with severe neurological and autoimmune diseases. Its focus areas include epilepsy, myasthenia gravis, psoriasis, hidradenitis suppurativa and osteoporosis, and its treatments include Bimzelx (bimekizumab). The company has more than 10,000 employees in about 40 countries, including a presence in Cambridge’s life sciences community.

Founded in 1928, UCB invests around a quarter of its revenue in research and development, spanning drug discovery, clinical development, digital health and partnerships with academic institutions and biotech companies. More than 3.1 million patients have accessed its solutions. The UCB Cares program supports people living with chronic diseases and their healthcare professionals throughout treatment, and a dedicated initiative advances research and care for women of childbearing age living with chronic conditions.

What to Know

• Sustainability is built into UCB’s business approach, covering access to medicines, employee wellbeing and the health of the planet.
• The company aims to move from treating symptoms toward disease modification and, ultimately, cures.
• UCB is listed with the Greater Boston Chamber of Commerce.